

Board of Directors Meeting in Public - Cover Sheet

Subject:	Research and Development Quarterly Update	Date: 28th February 2019		
Prepared By:	Alison Steel, Head of Research and Innovation			
Approved By:	David Hodgson, Research and Innovation Director			
Presented By:	Alison Steel, Head of Research and innovation			
Purpose				
Summary of R&I metrics and benchmarking performance (Q3)		Approval Assurance		X
Assurance of financial position at Q3		Update		
Identified Risks highlighted		Consider		
Industry trials update				
Workforce update				
R&I collaborations				
Strategic Objectives				
To provide outstanding care to our patients	To support each other to do a great job	To inspire excellence	To get the most from our resources	To play a leading role in transforming health and care services
X		X	X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Indicative budget from EMCRN of £ 686,317.65, 4.05% reduction for 19/20, excl NHS pay award Inability to build research capacity and capability over the next several years and develop the R&I business model if income generated from commercial trials is not directly used towards supporting R&I growth and funding delivery staff EU exit- assurances sought from sponsors around contingency plans for the supply and storage of IMP in clinical trials Work ongoing to identify Clinical Research Facility space. If delayed long term this will impede growth of the commercial research portfolio 			
Patient Impact	Decreased opportunity for our patient population to take part in research and access new and novel treatments, and increase quality of patient care at SFH			
Staff Impact	<ul style="list-style-type: none"> Risk to posts in R&I and support departments 2020/2021 if further NIHR budget reductions without the ability to use R&I Commercial trial income flexibly Currently appointing to the SFH Research academy Funding provided to support an ED and critical care nurse to assist with the delivery of research out of hours. 			
Services				

Reputational	Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN. Risk this may be affected if research portfolio and complexity remains static and staffing levels decrease
Committees/groups where this item has been presented before	
PSQG on 13th February 2019	
Executive Summary	
<p>Recruitment performance in Research and Innovation at SFH continues to increase. Q3 performance 2018/19:</p> <ol style="list-style-type: none"> 1. 1606 participants recruited in 18/19 c.f to 1226 in 17/18, 31% increase 2. 100% of annual target achieved by October 2018. 3. 71 studies are open at SFH with 70 actively recruiting 4. 75% of commercial and 74% of non-commercial studies are recruiting to 100% time and target 5. Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke. New areas opening studies e.g , Critical Care and Emergency Department 6. Charts 1-4 provide visual performance data 7. Chart 5 provides complexity weighting for 18/19 recruitment <p>Research activity in the organisation is increasing year on year, giving more patients the opportunity to participate in studies allowing them access to novel treatments and interventions.</p> <p>Commercial pharmaceutical and medical device research is also growing at SFH creating an excellent reputation for delivery with commercial sponsors, subsequently attracting new and renewed business. SFH is now being supported as a priority growth area by East Midlands Clinical Research Network. Progress against plan is detailed.</p> <p>Patient experience survey re-launched, 76 patients surveyed, overall 99.6% satisfaction. Detailed reporting planned for end of year</p> <p>The service we provide continues to deliver better outcomes for patients, allowing them access to new and different treatments. The reputation of the Research and Innovation department and SFH as a research active organisation continues to grow. We have strong associations with other NHS Trusts and Universities and are committed to expanding the research activity, breadth of our portfolio and facilities at SFH through delivering our research strategy.</p> <p>Studies show at a local level research can have positive outcomes in terms of increased quality of care, patient satisfaction and financial benefits to the organisation. It is well known that organisations that are research active provide better care to their patients', have better outcomes and better CQC ratings. It is important as a research active organisation that wherever possible we continue to make the changes and meet the requirements needed to advance our research activity and build research capacity for the future.</p>	